JAK2 V617F Constitutive Activation Requires JH2 Residue F595: A Pseudokinase Domain Target for Specific Inhibitors

The JAK2 V617F mutation present in over 95% of Polycythemia Vera patients and in 50% of Essential Thrombocythemia and Primary Myelofibrosis patients renders the kinase constitutively active. In the absence of a three-dimensional structure for the full-length protein, the mechanism of activation of J...

Descripción completa

Detalles Bibliográficos
Autores principales: Dusa, Alexandra, Mouton, Céline, Pecquet, Christian, Herman, Murielle, Constantinescu, Stefan N.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886835/
https://www.ncbi.nlm.nih.gov/pubmed/20585391
http://dx.doi.org/10.1371/journal.pone.0011157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886835/
https://www.ncbi.nlm.nih.gov/pubmed/20585391
http://dx.doi.org/10.1371/journal.pone.0011157

Ejemplares similares